Relationship between homocysteine and hypertensive disorder complicating pregnancy: a meta-analysis

doi:10.3969/j.issn.1004-583X.2021.02.001

Abstract

Abstract:

Objective To evaluate the correlation between plasma homocysteine (Hcy) levels and the risk of hypertensive disorder complicating pregnancy (HDCP). Methods PubMed, EMbase, Cochrane Library, Medline, Web of Science, CNKI, VIP and Wanfang data were searched for the literature which met inclusion and exclusion criteria. The quality evaluation of literature was carried out by Newcastle-Ottawa Scale. Rev Man 5.3 software was used to conduct meta-analysis. The included studies were analyzed to explore the correlation between plasma Hcy levels and risk of HDCP by the combination of the heterogeneity inspection and corresponding effect model. Results A total of 12 literature were included, all of which were of high quality (average score >5), with a total sample size of 10 079 cases. (1) The increase of plasma Hcy level was associated with the risk of HDCP(MD=4.44,95%CI: 3.01-5.87, P<0.01). (2)The plasma Hcy concentration in women with severe preeclampsia was higher than that in women with mild preeclampsia(MD=-2.84,95%CI:-3.78 - -1.90, P<0.01). (3) The correlation between serum folic acid and HDCP was statistically significant (MD=-3.21,95%CI:-4.50 - -1.91,P<0.01). (4) The correlation between serum Vit B12 level and HDCP was statistically significant (MD=-65.92,95%CI:-98.57 - -33.28, P<0.01). Conclusion Plasma Hcy level is closely related to the incidence of HDCP, its concentration is negatively correlated with serum levels of folic acid and Vit B12, and its expression level is significantly correlated with the severity of preeclampsia (PE). It is suggested that Hcy level may be a monitoring indicator for the efficacy and prognosis of PE.P

Key words: homocysteine, hypertension, pregnancy-induced, folic acid, Vit B12, meta-analysis

CLC Number:

R341.7

Zhou Yixuan, Lin Weizhao, Li Ruiman. Relationship between homocysteine and hypertensive disorder complicating pregnancy: a meta-analysis[J]. Clinical Focus, 2021, 36(2): 101-106.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.02.001

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I2/101

Figures/Tables 6

References 30

[1]	陈冬琳, 徐键. 同型半胱氨酸与妊娠相关疾病研究进展[J]. 预防医学, 2020,32(2):147-151.
[2]	Wisner K. Gestational hypertension and preeclampsia[J]. MCN Am J Matern Child Nurs, 2019,44(3):170. doi: 10.1097/NMC.0000000000000523 URL
[3]	White WM, Turner ST, Bailey KR, et al. Hypertension in pregnancy is associated with elevated homocysteine levels later in life[J]. Am J Obstet Gynecol, 2013,209(5):454.e1-7. doi: 10.1016/j.ajog.2013.06.030 URL
[4]	陈虹, 刘桂花, 王群. 血清同型半胱氨酸与高血压之间关系的相关分析[J]. 中国社区医师, 2019,35(13):124-125.
[5]	Skeete J DiPette DJ. Relationship between homocysteine and hypertension: new data add to the debate[J]. J Clin Hypertens (Greenwich), 2017,19(11):1171-1172. doi: 10.1111/jch.2017.19.issue-11 URL
[6]	Brown MA, Magee LA, Kenny LC, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice[J]. Pregnancy Hypertens, 2018,13:291-310. doi: S2210-7789(18)30126-0 pmid: 29803330
[7]	Lo CK, Mertz D, Loeb M. Newcastle-ottawa scale: comparing reviewers' to authors' assessments[J]. BMC Med Res Methodol, 2014,14:45. doi: 10.1186/1471-2288-14-45 URL
[8]	代延朋, 刘军杰, 袁恩武, 等. 同型半胱氨酸及血脂水平与妊娠期高血压疾病的相关性分析[J]. 实验与检验医学, 2019,37(2):265-267.
[9]	许雅娟, 洪腾, 翟闪闪, 等. 血清叶酸、同型半胱氨酸与妊娠期高血压疾病相关性研究[J]. 安徽医科大学学报, 2018,53(9):1479-1481.
[10]	董佳敏, 蔡薇. 血清同型半胱氨酸与妊娠期高血压疾病的相关性分析[J]. 浙江临床医学, 2017,19(3):528-529.
[11]	吴敬伟, 陈淑学. 妊娠期高血压疾病患者血浆总同型半胱氨酸与维生素 B12 水平的关系[J]. 中国妇幼保健, 2014,29(31):5048-5050.
[12]	张建鸿, 黄素然, 丁少波, 等. 妊娠期高血压疾病患者血浆总同型半胱氨酸水平监测及其干预治疗的研究[J]. 中国妇幼保健, 2008,23(5):610-612.
[13]	彭颖, 周湧, 黄素然等. 妊娠期高血压疾病患者血浆总同型半胱氨酸水平与叶酸和维生素B12 的关系[J]. 今日药学, 2010,20(6):51-53.
[14]	周天祥, 张修发, 翟庆娜等. 同型半胱氨酸、C 反应蛋白与妊娠期高血压疾病的关系[J]. 蚌埠医学院学报, 2016,41(5):664-665.
[15]	杨红星, 黄素然, 丁少波, 等. 妊娠期高血压疾病患者血浆总同型半胱氨酸浓度的监测及其影响因素分析[J]. 中国药物应用与监测, 2008,5(2):1-2.
[16]	Sun F, Qian W, Zhang C, et al. Correlation of maternal serum homocysteine in the first trimester with the development of gestational hypertension and preeclampsia[J]. Med Sci Monit, 2017,23:5396-5401. doi: 10.12659/MSM.905055 URL
[17]	Zeng Y, Li M, Chen Y, et al. Homocysteine, endothelin-1 and nitric oxide in patients with hypertensive disorders complicating pregnancy[J]. Int J Clin Exp Pathol, 2015,8(11):15275-15279.
[18]	Hoque MM, Bulbul T, Mahal M, et al. Serum homocysteine in pre-eclampsia and eclampsia[J]. Bangladesh Med Res Counc Bull, 2008,34(1):16-20. doi: 10.3329/bmrcb.v34i1.1165 URL
[19]	Sanchez SE, Zhang C, Rene Malinow M, et al. Plasma folate, vitamin B(12), and homocyst(e)ine concentrations in preeclamptic and normotensive Peruvian women[J]. Am J Epidemiol, 2001,153(5):474-480. pmid: 11226979
[20]	Wu F, Yang H, Liu B. Association between homocysteine and arterial stiffness in women with a history of preeclampsia[J]. J Vasc Res, 2019,56(3):152-159. doi: 10.1159/000500358 URL
[21]	Acilmis YG, Dikensoy E, Kutlar AI, et al. Homocysteine, folic acid and vitamin B12 levels in maternal and umbilical cord plasma and homocysteine levels in placenta in pregnant women with pre-eclampsia[J]. J Obstet Gynaecol Res, 2011,37(1):45-50. doi: 10.1111/jog.2011.37.issue-1 URL
[22]	Mascarenhas M, Habeebullah S, Sridhar MG. Revisiting the role of first trimester homocysteine as an index of maternal and fetal outcome[J]. J Pregnancy, 2014: 123024.
[23]	Dymara-Konopka W, Laskowska M. The role of nitric oxide, ADMA, and homocysteine in the etiopathogenesis of preeclampsia-review[J]. Int J Mol Sci, 2019,20(11):2757. doi: 10.3390/ijms20112757 URL
[24]	Maged AM. Maternal serum homocysteine and uterine artery Doppler as predictors of preeclampsia and poor placentation[J]. Arch Gynecol Obstet, 2018,297(1):275. doi: 10.1007/s00404-017-4609-0 URL
[25]	Serrano NC, Quintero-Lesmes DC, Becerra-Bayona S, et al. Association of pre-eclampsia risk with maternal levels of folate, homocysteine and vitamin B12 in Colombia: A case-control study[J]. PLoS One, 2018,13(12):e0208137. doi: 10.1371/journal.pone.0208137 URL
[26]	Sayyah-Melli M, Ghorbanihaghjo A, Alizadeh M, et al. The effect of high dose folic acid throughout pregnancy on homocysteine (hcy) concentration and pre-eclampsia: a randomized clinical trial[J]. PLoS One, 2016,11(5):e0154400. doi: 10.1371/journal.pone.0154400 URL
[27]	Singh MD, Thomas P, Owens J, et al. Potential role of folate in pre-eclampsia[J]. Nutr Rev, 2015,73(10):694-722. doi: 10.1093/nutrit/nuv028 URL
[28]	De Ocampo MPG, Araneta MRG, Macera CA, et al. Folic acid supplement use and the risk of gestational hypertension and preeclampsia[J]. Women Birth, 2018,31(2):e77-e83. doi: 10.1016/j.wombi.2017.08.128 URL
[29]	李国选, 高祖标, 谢振荣, 等. 血浆同型半胱氨酸含量的变化与妊娠期高血压疾病的预后[J]. 中国优生与遗传杂志, 2007,15(4):31-32.
[30]	Mignini LE, Latthe PM, Villar J, et al. Mapping the theories of preeclampsia: the role of homocysteine[J]. Obstet Gynecol, 2005,105(2):411-425. doi: 10.1097/01.AOG.0000151117.52952.b6 URL

纳入研究	组别(例)		产妇年龄(岁)		产妇孕周(周)		BMI(kg/m²)		Hcy测量方法	质量评分
纳入研究	观察组	对照组	观察组	对照组	观察组	对照组	观察组	对照组	Hcy测量方法	质量评分
代延鹏 2019^[8]	750	316	27.41±2.47	28.01±2.47	32.14±1.36	32.66±1.41			酶学测定	8
许雅娟 2018^[9]	215	166	30.92±4.64	30.19±4.68	31.73±4.48	31.15±4.57	26.06±1.58	25.92±1.56	酶学测定	9
董佳敏 2017^[10]	230	200	26.40±2.20	27.80±1.70	35.40±1.60	36.0±2.0	22.0±1.5	21.0±1.7	循环酶法	8
吴敬伟 2014^[11]	232	232							荧光偏振免疫分析法( FPIA)	7
张建鸿 2008^[12]	350	350	25.40±4.70	24.30±2.10	34.10±2.70	35.6±4.0			荧光偏振免疫分析法( FPIA)	9
彭颖 2010^[13]	232	250							荧光偏振免疫分析法( FPIA)	7
周天祥 2016^[14]	126	119	20~35	22~35					循环酶法	8
杨红星 2008^[15]	266	250							荧光偏振免疫分析法( FPIA)	8
Sun 2017^[16]	294	4 418	31.18±3.95	30.37±3.73			22.97±3.41	20.84±2.52	循环酶法	9
Zeng 2015^[17]	239	200	26.50±2.20	27.90±1.70	35.50±1.60	36.1±2.0	22.1±1.5	21.0±1.7	循环酶法	9
Hoque 2008^[18]	204	136	25.08±5.18	25.84±5.43	30.46±4.05	30.80±4.03	24.48±1.9	21.7±1.7	酶学测定	9
Sanchez 2001^[19]	125	179	<19(n=21) 19~34(n=84) ≥35(n=20)	<19(n=26) 19~34(n=125) ≥35(n=28)	36.00±0.30	37.3±0.3			循环酶法	6

纳入研究	组别(例)		产妇年龄(岁)		产妇孕周(周)		BMI(kg/m²)		Hcy测量方法	质量评分
纳入研究	观察组	对照组	观察组	对照组	观察组	对照组	观察组	对照组	Hcy测量方法	质量评分
代延鹏 2019^[8]	750	316	27.41±2.47	28.01±2.47	32.14±1.36	32.66±1.41			酶学测定	8
许雅娟 2018^[9]	215	166	30.92±4.64	30.19±4.68	31.73±4.48	31.15±4.57	26.06±1.58	25.92±1.56	酶学测定	9
董佳敏 2017^[10]	230	200	26.40±2.20	27.80±1.70	35.40±1.60	36.0±2.0	22.0±1.5	21.0±1.7	循环酶法	8
吴敬伟 2014^[11]	232	232							荧光偏振免疫分析法( FPIA)	7
张建鸿 2008^[12]	350	350	25.40±4.70	24.30±2.10	34.10±2.70	35.6±4.0			荧光偏振免疫分析法( FPIA)	9
彭颖 2010^[13]	232	250							荧光偏振免疫分析法( FPIA)	7
周天祥 2016^[14]	126	119	20~35	22~35					循环酶法	8
杨红星 2008^[15]	266	250							荧光偏振免疫分析法( FPIA)	8
Sun 2017^[16]	294	4 418	31.18±3.95	30.37±3.73			22.97±3.41	20.84±2.52	循环酶法	9
Zeng 2015^[17]	239	200	26.50±2.20	27.90±1.70	35.50±1.60	36.1±2.0	22.1±1.5	21.0±1.7	循环酶法	9
Hoque 2008^[18]	204	136	25.08±5.18	25.84±5.43	30.46±4.05	30.80±4.03	24.48±1.9	21.7±1.7	酶学测定	9
Sanchez 2001^[19]	125	179	<19(n=21) 19~34(n=84) ≥35(n=20)	<19(n=26) 19~34(n=125) ≥35(n=28)	36.00±0.30	37.3±0.3			循环酶法	6